Boehringer Ingelheim’s Novel Glucagon/GLP-1 Dual Agonist Survodutide Achieved Significant Weight Loss and Meaningful Metabolic Improvement in Phase III Trial
Summary
Boehringer Ingelheim today announced positive topline results from the Phase III SYNCHRONIZE-1 trial, in which survodutide (BI 456906) met the co-primary endpoi
Description
Boehringer Ingelheim today announced positive topline results from the Phase III SYNCHRONIZE-1 trial, in which survodutide (BI 456906) met the co-primary endpoi
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source